1 week Ago By ABMN Staff
Prudential Financial Inc. trimmed its stake in Avidity Biosciences, Inc. ( NASDAQ:RNA – Free Report ) by 24.
3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,880 shares of the biotechnology company’s stock after selling 3,500 shares during the period. Prudential Financial Inc.
’s holdings in Avidity Biosciences were worth $316,000 as of its most recent SEC filing. A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc.
raised its holdings in shares of Avidity Biosciences by 2.2% during the 4th quarter. Vanguard Group Inc.
now owns 9,431,911 shares of the biotechnology company’s stock valued at $274,280,000 after buying an additional 205,027 shares in the last quarter. State Street Corp raised its stake in Avidity Biosciences by 41.7% in the third quarter.
State Street Corp now owns 4,706,106 shares of the biotechnology company’s stock worth $216,151,000 after buying an additional 1,386,087 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Avidity Biosciences by 14.6% in the 3rd quarter.
Geode Capital Management LLC now owns 2,585,303 shares of the biotechnology company’s stock valued at $118,767,000 after purchasing an additional 328,606 shares during the period. Charles Schwab Investment Management Inc. lifted its position in Avidity Biosciences by 3.
9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,028,931 shares of the biotechnology company’s stock valued at $29,921,000 after buying an additional 38,749 shares during the period.
Finally, Lord Abbett & CO. LLC lifted its position in Avidity Biosciences by 30.1% during the 3rd quarter.
Lord Abbett & CO. LLC now owns 539,207 shares of the biotechnology company’s stock valued at $24,766,000 after acquiring an additional 124,867 shares during the period. Wall Street Analysts Forecast Growth Several research firms have commented on RNA.
Chardan Capital reissued a “buy” rating and issued a $65.00 target price on shares of Avidity Biosciences in a report on Monday, March 17th. HC Wainwright restated a “buy” rating and issued a $72.
00 target price on shares of Avidity Biosciences in a report on Monday, March 17th. Citigroup assumed coverage on shares of Avidity Biosciences in a research report on Thursday, March 13th. They set a “buy” rating and a $70.
00 price target for the company. Bank of America reduced their price objective on Avidity Biosciences from $51.00 to $48.
00 and set a “buy” rating for the company in a research note on Monday, March 10th. Finally, Barclays decreased their target price on shares of Avidity Biosciences from $63.00 to $57.
00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Thirteen investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $66.
69. Avidity Biosciences Stock Down 2.8 % Avidity Biosciences stock opened at $24.
11 on Friday. Avidity Biosciences, Inc. has a 52-week low of $21.
51 and a 52-week high of $56.00. The firm’s fifty day moving average is $30.
46 and its 200 day moving average is $35.93. The company has a market cap of $2.
90 billion, a price-to-earnings ratio of -8.37 and a beta of 1.01.
Avidity Biosciences ( NASDAQ:RNA – Get Free Report ) last announced its earnings results on Thursday, February 27th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.
76) by ($0.04). The business had revenue of $2.
97 million for the quarter, compared to analysts’ expectations of $1.74 million. Avidity Biosciences had a negative net margin of 2,772.
45% and a negative return on equity of 27.66%. On average, equities research analysts anticipate that Avidity Biosciences, Inc.
will post -2.89 earnings per share for the current fiscal year. Insider Activity In related news, CEO Sarah Boyce sold 31,540 shares of Avidity Biosciences stock in a transaction dated Thursday, March 20th.
The shares were sold at an average price of $31.06, for a total transaction of $979,632.40.
Following the completion of the transaction, the chief executive officer now directly owns 305,871 shares of the company’s stock, valued at approximately $9,500,353.26. The trade was a 9.
35 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website . Also, Director Arthur A.
Levin sold 1,872 shares of the company’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $28.60, for a total transaction of $53,539.
20. Following the transaction, the director now owns 12,958 shares in the company, valued at $370,598.80.
The trade was a 12.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here .
Insiders sold 79,318 shares of company stock valued at $2,405,390 in the last ninety days. Insiders own 3.68% of the company’s stock.
About Avidity Biosciences ( Free Report ) Avidity Biosciences, Inc, a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial.
Further Reading Receive News & Ratings for Avidity Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avidity Biosciences and related companies with MarketBeat.com's FREE daily email newsletter ..
